Clinical Trials Logo

People Who Inject Drugs clinical trials

View clinical trials related to People Who Inject Drugs.

Filter by:
  • None
  • Page 1

NCT ID: NCT06131788 Not yet recruiting - Clinical trials for People Who Inject Drugs

Evaluation of an Educational Intervention on Abscesses in People Who Self-inject Drugs

HAWA
Start date: January 2024
Phase: N/A
Study type: Interventional

The goal of this cluster randomised controlled trial (cRCT) is to to evaluate the effectiveness of an educational intervention combining training in hand-washing with the supply of MONO-RUBs on the reduction of skin abscesses (both observed and self-reported) in people who inject drugs (PWID). The main questions it aims to answer are: - does an educational intervention change the incidence of injection-related skin and soft tissue infection (SSTI) like abscesses in PWID? - does the educational hand-washing intervention improve injection practices in terms of hand-hygiene in PWID? According to cluster randomisation, PWID will be assigned to: - Standard harm reduction (HR) services to reduce abscesses plus an educational hand-washing intervention (intervention arm) - Standard HR services only (control arm) To measure the effectiveness of the educational hand-washing intervention, the primary outcome will be the reduction in abscess prevalence compared in both groups. Statistical analyses for the primary outcome will involve comparing the reduction in abscess prevalence in the intervention arm with that in the control arm. This prevalence will be measured from observed and self-declared data, collected from the injection-site photographs and the face-to-face injection-related SSTI questionnaire, respectively.

NCT ID: NCT05895448 Active, not recruiting - Chronic Hepatitis C Clinical Trials

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

Start date: March 1, 2018
Phase: Phase 4
Study type: Interventional

Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (IC). This cohort was compared to concurrently treated chronic hepatitis C patients who were not intravenous drug users, who signed IC in these same clinics. Follow-up expected two years after cure and relapse rates recorded. Primary end point was SVR rate and secondary end points included reinfection rates in follow-up period.

NCT ID: NCT03214679 Completed - Hepatitis C Clinical Trials

Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)

Start date: July 20, 2017
Phase: N/A
Study type: Interventional

The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs designed specifically for PWID where they can comfortably access care without fear of shame or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle exchange program. The proposed study will compare the effectiveness of Accessible Care with Usual Care (referrals to existing services) in facilitating linkage, engagement, and retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome is sustained virologic response, which constitutes virologic cure. Substance use and HIV and HCV risk behaviors are secondary outcomes.